Gerry Ryan -the owner of the Orica-GreenEdge team, fears that British rider Simon Yates’ adverse analytic finding for the asthma medication Terbutaline is a case that risks being judged in a “kangaroo court” due to its leaking to the media.
“There has been no B sample, “Ryan told Cyclingnews by telephone on Friday morning. “But once again, pardon the pun, it’s going to be a kangaroo court. I believe in the system of the UCI. Hopefully it goes through the process.”
Ryan is in Yorkshire with the Orica-GreenEdge team for the Tour de Yorkshire that starts today. Asked if his faith in the team is rock solid in light of events, Ryan insisted it is, and said he will remind the riders that they are “here to race a race.”
ADVERTISEMENT
Orica-GreenEdge confirmed Yates’ test result in a team statement that was released on Thursday evening.
The statement said the team was notified of the adverse analytical finding on April 22 for a test carried out on March 6, on stage six of Paris-Nice, and that the substance was Terbutaline.
Terbutaline can be used to treat asthma, but it is banned in competition, unless riders have a therapeutic use exemption (TUE) for it.
You can read more at Cyclingnews.com
via Cyclingnews Latest News http://ift.tt/1UlTqBf
No comments:
Post a Comment